Literature DB >> 20446517

Prostate cancer diagnosis.

Peter A Humphrey1, Gerald L Andriole.   

Abstract

Prostate cancer is the fourth most common malignancy diagnosed in Missouri. The diagnosis may be clinically suspected based on an elevated serum prostate specific antigen (PSA) and/or digital rectal examination abnormality. Clinical symptoms are usually a manifestation of more advanced disease. The diagnosis is typically established by histopathologic examination of needle biopsy tissue. This article reviews clinical and pathological approaches to prostate cancer diagnosis, with a focus on clinically localized disease and needle biopsy diagnosis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20446517      PMCID: PMC6188279     

Source DB:  PubMed          Journal:  Mo Med        ISSN: 0026-6620


  19 in total

1.  Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy.

Authors:  Andrew J Stephenson; Peter T Scardino; James A Eastham; Fernando J Bianco; Zohar A Dotan; Paul A Fearn; Michael W Kattan
Journal:  J Natl Cancer Inst       Date:  2006-05-17       Impact factor: 13.506

2.  Updated nomogram to predict pathologic stage of prostate cancer given prostate-specific antigen level, clinical stage, and biopsy Gleason score (Partin tables) based on cases from 2000 to 2005.

Authors:  Danil V Makarov; Bruce J Trock; Elizabeth B Humphreys; Leslie A Mangold; Patrick C Walsh; Jonathan I Epstein; Alan W Partin
Journal:  Urology       Date:  2007-06       Impact factor: 2.649

3.  Mortality results from a randomized prostate-cancer screening trial.

Authors:  Gerald L Andriole; E David Crawford; Robert L Grubb; Saundra S Buys; David Chia; Timothy R Church; Mona N Fouad; Edward P Gelmann; Paul A Kvale; Douglas J Reding; Joel L Weissfeld; Lance A Yokochi; Barbara O'Brien; Jonathan D Clapp; Joshua M Rathmell; Thomas L Riley; Richard B Hayes; Barnett S Kramer; Grant Izmirlian; Anthony B Miller; Paul F Pinsky; Philip C Prorok; John K Gohagan; Christine D Berg
Journal:  N Engl J Med       Date:  2009-03-18       Impact factor: 91.245

Review 4.  Prostate-specific antigen: a review of the validation of the most commonly used cancer biomarker.

Authors:  Javier Hernández; Ian M Thompson
Journal:  Cancer       Date:  2004-09-01       Impact factor: 6.860

5.  Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy.

Authors:  Anthony V D'Amico; Ming-Hui Chen; Kimberly A Roehl; William J Catalona
Journal:  N Engl J Med       Date:  2004-07-08       Impact factor: 91.245

6.  Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer.

Authors:  J I Epstein; P C Walsh; M Carmichael; C B Brendler
Journal:  JAMA       Date:  1994-02-02       Impact factor: 56.272

7.  PSA failure following definitive treatment of prostate cancer having biopsy Gleason score 7 with tertiary grade 5.

Authors:  Abhijit A Patel; Ming-Hui Chen; Andrew A Renshaw; Anthony V D'Amico
Journal:  JAMA       Date:  2007-10-03       Impact factor: 56.272

Review 8.  Prostate-specific antigen and prostate cancer: prediction, detection and monitoring.

Authors:  Hans Lilja; David Ulmert; Andrew J Vickers
Journal:  Nat Rev Cancer       Date:  2008-04       Impact factor: 60.716

9.  Prostate cancer screening in the Prostate, Lung, Colorectal and Ovarian cancer screening trial: update on findings from the initial four rounds of screening in a randomized trial.

Authors:  Robert L Grubb; Paul F Pinsky; Robert T Greenlee; Grant Izmirlian; Anthony B Miller; Thomas P Hickey; Thomas L Riley; Jerome E Mabie; David L Levin; David Chia; Barnett S Kramer; Douglas J Reding; Timothy R Church; Lance A Yokochi; Paul A Kvale; Joel L Weissfeld; Donald A Urban; Saundra S Buys; Edward P Gelmann; Lawrence R Ragard; E David Crawford; Philip C Prorok; John K Gohagan; Christine D Berg; Gerald L Andriole
Journal:  BJU Int       Date:  2008-12       Impact factor: 5.588

10.  Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter.

Authors:  Ian M Thompson; Donna K Pauler; Phyllis J Goodman; Catherine M Tangen; M Scott Lucia; Howard L Parnes; Lori M Minasian; Leslie G Ford; Scott M Lippman; E David Crawford; John J Crowley; Charles A Coltman
Journal:  N Engl J Med       Date:  2004-05-27       Impact factor: 91.245

View more
  6 in total

Review 1.  α-Synuclein and DJ-1 as potential biological fluid biomarkers for Parkinson's Disease.

Authors:  Masaaki Waragai; Kazunari Sekiyama; Akio Sekigawa; Yoshiki Takamatsu; Masayo Fujita; Makoto Hashimoto
Journal:  Int J Mol Sci       Date:  2010-10-29       Impact factor: 5.923

2.  Quantitative metric profiles capture three-dimensional temporospatial architecture to discriminate cellular functional states.

Authors:  Lindsey McKeen-Polizzotti; Kira M Henderson; Basak Oztan; C Cagatay Bilgin; Bülent Yener; George E Plopper
Journal:  BMC Med Imaging       Date:  2011-05-20       Impact factor: 1.930

Review 3.  The application of SELDI-TOF-MS in clinical diagnosis of cancers.

Authors:  Chibo Liu
Journal:  J Biomed Biotechnol       Date:  2011-05-23

4.  Transperineal ultrasound-guided 12-core prostate biopsy: an extended approach to diagnose transition zone prostate tumors.

Authors:  Ming-Hua Yao; Li-Ling Zou; Rong Wu; Le-Hang Guo; Guang Xu; Juan Xie; Pei Li; Shuai Wang
Journal:  PLoS One       Date:  2014-02-25       Impact factor: 3.240

5.  The Role of Mass Spectrometry in the "Omics" Era.

Authors:  Francesco Di Girolamo; Isabella Lante; Maurizio Muraca; Lorenza Putignani
Journal:  Curr Org Chem       Date:  2013-12       Impact factor: 2.180

Review 6.  Immunochemical Assays and Nucleic-Acid Detection Techniques for Clinical Diagnosis of Prostate Cancer.

Authors:  Prosper Kanyong; Sean Rawlinson; James Davis
Journal:  J Cancer       Date:  2016-02-10       Impact factor: 4.207

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.